Evidence map›Paper›PMID 33931984›Full record

ArticleCancer reports (Hoboken, N.J.)2021

Can the predictive value of multiparametric MRI for prostate cancer be improved by a liquid biopsy with SelectMDx?

Mohammad Sajjad Rahnama'i, Christian Bach, Maximilian Schulze-Hagen, Christiane K Kuhl, Thomas Alexander Vögeli

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer reports (Hoboken, N.J.), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 2 pooled it
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 2 syntheses or guidelines pooled it, 9 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Review
  4. Review
  5. Article
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors at 1 institution in 1 country.

Mohammad Sajjad Rahnama'iDepartment of Urology, Uniklinik RWTH, Aachen, Germany.ORCID 0000-0003-1953-7441
Christian BachDepartment of Urology, Uniklinik RWTH, Aachen, Germany.
Maximilian Schulze-HagenDepartment of Radiology, Uniklinik RWTH, Aachen, Germany.
Christiane K KuhlDepartment of Radiology, Uniklinik RWTH, Aachen, Germany.
Thomas Alexander VögeliDepartment of Urology, Uniklinik RWTH, Aachen, Germany.
Universitätsklinikum Aachen · DE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundSelectMDx is a urinary biomarker test for determining prostate cancer risk.

aimIn a group of patients with a biopsy proven prostate cancer (PCa) who had undergone a multi parametric Magnetic Resonance Imaging (mpMRI) and urinary biomarker test with SelectMDx, we studied the additive value of SelectMDx to mpMRI and correlated that to the radical prostatectomy histology. METHODS AND

resultsThirty-nine consecutive patients with a positive prostate biopsy were included in the study. They all had mpMRI and SelectMDx and underwent a radical prostatectomy. Overall, the mpMRI showed a PIRADS ≤3 lesion in seven cases out of the 39 patients. Significant lesions (PIRADS ≥4) were found in 32 cases (82%), that is, in 17 cases a PIRADS 5 lesion and in 15 cases a PIRADS 4 lesion. The mpMRI missed significant PCa in seven cases (18%) who had a PIRADS ≤3 lesion but had a significant PCa on final histology after RP. In our study, the positive predictive values of mpMRI were 97% and that of the SelectMDx was 100%.

conclusionIn this real-life selected group of consecutive patients with a confirmed positive PCa biopsy and available mpMRI, the liquid biopsy test with SelectMDx, did not provide an additional information about the PCa clinical significance. The addition of SelectMDx was only found valuable in those patients who had a very high-risk PCa (ie, GS ≥8) who had a positive SelectMDx test outcome despite of a negative mpMRI outcome.

Indexed as

AgedBiomarkers, TumorFollow-Up StudiesHumansLiquid BiopsyMaleMiddle AgedMultiparametric Magnetic Resonance ImagingPrognosisProstatectomyProstatic NeoplasmsBiomarkers, TumorbiomarkersmpMRIprostate cancerSelectMdxurinary marker

Identifiers

PMID33931984
PMCPMC8714534
OpenAlexW3159617156

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.